FIVE years ago Atkinson and Robertson surveyed the use of captopril, the first orally active
inhibitor of the renin-angiotensin system, in the treatment of clinical hypertension and …

Ninety-two patients with heart failure refractory to digitalis and diuretic therapy had Captopril
(n= 50) or placebo (n= 42) added to their therapeutic regimen in a randomized, double-blind …

Teprotide, a nonapeptide isolated from the venom of a Brazilian pit viper, Bothrops jararaca,
was the first angiotensin converting enzyme (ACE) inhibitor to be discovered and tested. It …

The effect of the converting enzyme inhibitor captopril as long term treatment was
investigated in 14 patients with severe congestive heart failure in a double blind trial …

Several studies have shown symptomatic and haemodynamic improvement after the
introduction of angiotensin converting enzyme inhibitors in patients with heart failure treated …

Objectives. This study was performed to the efficacy, safety and clinical consequences of
abrupt cessation of quinapril therapy in a placebo-controlled,, randomized, double-blind …

Background Heart failure (HF) therapy involves use of multiple medications. There is little
guidance on the safety and impact on clinical outcomes of stopping HF medications …

The role of hemodynamic monitoring during the initiation of vasodilator therapy for heart
failure remains to be defined, despite the tremendous potential socioeconomic and clinical …

Abstract Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting
millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the …

Hemodynamic effects of the new oral angiotensin-con-verting enzyme inhibitor, enalapril,
were evaluated acutely in 15 patients with chronic heart failure and in 7 patients after 4 …